Healthcare Sales & Marketing Network News: mucositis

Searching News Database: mucositis

HSMN NewsFeed - 8 Jul 2025
Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 Jan 2025
FDA Approves LUMAKRAS(R) (Sotorasib) in Combination with Vectibix(R) (Panitumumab) for Chemorefractory KRAS G12C-Mutated Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 4 May 2023
Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte(TM) in the Treatment of Cutaneous T-Cell Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 14 Apr 2023
Soligenix Provides Regulatory Update on HyBryte(TM)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 14 Feb 2023
Soligenix Receives Refusal to File Letter from U.S. FDA for HyBryte(TM) New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Sep 2021
LUMAKRAS(TM) (Sotorasib) Combined With Vectibix(R) (Panitumumab) Showed Encouraging Efficacy And Safety In Patients With KRAS G12C-Mutated Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Feb 2021
BrainCool AB (publ) Receives FDA "Breakthrough Device" Designation for Cooral(R) System for Prevention of Oral Mucositis
Devices FDA

HSMN NewsFeed - 22 Dec 2020
Soligenix Announces Topline Results from its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Dec 2020
BAVENCIO(R) (avelumab) Receives Positive CHMP Opinion for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 18 Sep 2020
BrainCool Announces Statistically Significant Late-Breaking Clinical Data at ESMO Virtual Congress 2020
Devices Oncology

HSMN NewsFeed - 15 May 2020
Soligenix Announces Recent Accomplishments And First Quarter 2020 Financial Results
Biopharmaceuticals

HSMN NewsFeed - 30 Apr 2020
Soligenix Announces Positive Phase 3 FLASH Study Demonstrates Increased Efficacy with Continued Treatment in Patients with Cutaneous T-Cell Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Apr 2020
EMD Serono and Pfizer Receive US FDA Breakthrough Therapy Designation and Submit Application for BAVENCIO(R) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 13 Mar 2020
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Sep 2019
Soligenix Appoints Daniel P. Ring as Vice President of Business Development and Strategic Planning
Biopharmaceuticals Personnel

HSMN NewsFeed - 11 Sep 2019
Soligenix Appoints Jonathan Guarino as Chief Financial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 8 Jul 2019
Soligenix Announces Appointment of Diane L. Parks to its Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 30 May 2019
U.S. FDA Approves Supplemental New Drug Application Adding Overall Survival Data for XOSPATA(R) (gilteritinib)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 18 Jan 2019
Lilly Reports Results of Phase 3 Soft Tissue Sarcoma Study of LARTRUVO(R)
Biopharmaceuticals Oncology

HSMN NewsFeed - 15 Oct 2018
Soligenix Announces Positive Recommendation by Independent Data Monitoring Committee on its Phase 3 Clinical Trial of SGX301 for the Treatment of Cutaneous T-cell Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 24 Jul 2018
Soligenix Announces Appointment of Mark Pearson to its Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 20 Jul 2018
FDA Grants Approval of TIBSOVO(R), the First Oral, Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH1 Mutation
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 5 Jun 2018
FDA Expands Lilly's ALIMTA(R) (pemetrexed) Label to Include Combination with KEYTRUDA(R) (pembrolizumab) and Carboplatin as First-Line Treatment for Metastatic Nonsquamous Non-Small Cell Lung Cancer, Irrespective of PD-L1 Expression
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 23 Jun 2017
EUSA Pharma Receives Positive CHMP Opinion for Tivozanib for the First-Line Treatment of Advanced Renal Cell Carcinoma in Europe
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 19 Jun 2017
Complete Efficacy and Long-Term Follow-Up Safety Results from SGX942 Phase 2 Oral Mucositis Clinical Trial to be Presented at the 2017 Multinational Association for Supportive Care in Cancer Conference
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 May 2017
Soligenix Receives FDA Protocol Clearance of Pivotal Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 28 Apr 2017
Novartis Receives FDA Approval for Rydapt(R) in Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML) and Three Types of Systemic Mastocytosis (SM)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 6 Mar 2017
Izun Pharmaceuticals Announces Approval of Curasite(TM) Hydrogel Wound Care Product by FDA
Biopharmaceuticals Wound Care FDA

HSMN NewsFeed - 1 Dec 2016
Helsinn Integrative Care Announces 510(K) FDA Clearance for Medical Device Xonrid(R) Gel
Devices Oncology Dermatology FDA Product Launch

HSMN NewsFeed - 10 Oct 2016
First Positive Phase 3 Results in Adjuvant Setting for Renal Cell Carcinoma Show SUTENT(R) (sunitinib) Extended Disease Free Survival After Surgical Removal
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Oct 2016
EUSA Pharma Acquires Global Rights to Neuroblastoma Treatment Isqette(R) (Dinutuximab Beta) from Apeiron Biologics
Biopharmaceuticals Oncology Acqusitions

HSMN NewsFeed - 12 Sep 2016
Soligenix and SciClone Establish Regional Licensing Agreement for SGX942, a Novel Product Candidate for Oral Mucositis
Biopharmaceuticals Licensing

HSMN NewsFeed - 18 Aug 2016
FDA Grants Soligenix Orphan Drug Designation for Dusquetide for Treatment of Macrophage Activation Syndrome
Biopharmaceuticals FDA

HSMN NewsFeed - 23 Jan 2016
Cellceutix Releases Data Used in Receiving FDA Orphan Drug Designation of Kevetrin for Pancreatic Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 14 Oct 2015
Galera Therapeutics Raises $37 Million in Series B Financing
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 3 Aug 2015
Soligenix Enters into a $10 Million Equity Purchase Agreement
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 23 Mar 2015
EUSA Pharma Successfully Launches as an Independent Profitable Pharmaceutical Business with Global Reach and a Portfolio of Specialty Products Acquired from Jazz Pharmaceuticals
Biopharmaceuticals Acquisitions Product Launch

HSMN NewsFeed - 29 Sep 2014
AMAG Pharmaceuticals to Acquire Lumara Health Maternal Health Business
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 23 Sep 2014
Soligenix Appoints Rasappa Arumugham, PhD, as Vice President of Biopharmaceutical Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 8 Sep 2014
AMAG Pharmaceuticals Announces Appointment of John A. Fallon, M.D. to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 12 Aug 2014
AMAG Pharmaceuticals Appoints Robert Blood as Vice President of Legal Affairs and Chief Compliance Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 19 Mar 2014
BioAlliance Pharma: Sitavig(R) Licensing Strategy
Biopharmaceuticals Dermatology Licensing

HSMN NewsFeed - 20 Feb 2014
Bayer Initiates Phase III Trial of Stivarga(R) (regorafenib) Tablets in Patients with Colorectal Cancer after Resection of Liver Metastases
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 Feb 2014
BMG PHARMA S.r.l - Milan, Italy - Has Granted Exclusive Distribution Rights to Samyang Biopharmaceutical Corporation for GelX(R) in the Territory of South Korea
Biopharmaceuticals Licensing Distribution

HSMN NewsFeed - 7 Jan 2014
AMAG Pharmaceuticals Appoints Elizabeth Bolgiano as Senior Vice President of Human Resources
Biopharmaceuticals Personnel

HSMN NewsFeed - 6 Jan 2014
Soligenix Appoints Richard Straube, MD, as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 20 Dec 2013
Cellceutix Files Orphan Drug Designation Application for Brilacidin for Oral Mucositis with US FDA
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 22 Nov 2013
Threshold Pharmaceuticals Announces New Clinical Data on TH-302 and Avastin(R) (Bevacizumab) in Recurrent Glioblastoma Following Bevacizumab Failure
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Oct 2013
AMAG Pharmaceuticals Appoints Robert F. Kaper, M.D. as Senior Vice President of Medical and Scientific Affairs
Biopharmaceuticals Personnel

HSMN NewsFeed - 21 Oct 2013
Soligenix Announces Appointment of Marco Maria Brughera to its Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 3 Oct 2013
Soligenix Appoints Oreola Donini, PhD, as Vice President of Preclinical Research and Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 16 Sep 2013
FDA Grants Soligenix Orphan Drug Designation for SGX94 for Treatment of Acute Radiation Syndrome
Biopharmaceuticals FDA

HSMN NewsFeed - 30 Aug 2013
Bayer's Stivarga(R) (regorafenib) Tablets Approved in Europe
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 23 Jul 2013
AMAG Pharmaceuticals Appoints Carol Satler, M.D., Ph.D. as Senior Vice President of Medical and Scientific Affairs
Biopharmaceuticals Personnel

HSMN NewsFeed - 24 Jun 2013
AMAG Pharmaceuticals Appoints Steven Caffe, M.D. as Chief Development and Regulatory Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 15 May 2013
Bayer Initiates Phase III Trial of Stivarga(R) (regorafenib) Tablets in Patients with Advanced Liver Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 14 Mar 2013
Spectrum Pharmaceuticals Gains Rights to Pivotal-Stage Captisol-Enabled(R) Melphalan
Biopharmaceuticals Licensing

HSMN NewsFeed - 29 Jan 2013
FDA Grants Soligenix Fast Track Designation for OrbeShield(TM) for the Reduction of Mortality Associated with Gastrointestinal Acute Radiation Syndrome (GI ARS)
Biopharmaceuticals FDA

HSMN NewsFeed - 11 Jan 2013
Spectrum Pharmaceuticals Announces Promotion of Joseph Turgeon to Senior Vice President and Chief Commercial Officer as Company Builds on Recent Commercial Reorganization to Advance Growth and Market Penetration over the Next Five Years
Biopharmaceuticals Personnel

HSMN NewsFeed - 2 Jan 2013
FDA Grants Soligenix Orphan Drug Designation for OrbeShield(TM) for Treatment after Exposure to a Radiological Disaster
Biopharmaceuticals FDA

HSMN NewsFeed - 18 Dec 2012
Avaxia Biologics Raises $6.4 Million in Series B Financing
Biopharmaceuticals Gastroenterology Venture Capital

HSMN NewsFeed - 11 Dec 2012
Galera Therapeutics Raises $11 Million in Series A Financing
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 29 Oct 2012
Bayer's Stivarga(R) (regorafenib) Tablets New Drug Application Granted Priority Review by U.S. FDA for the Treatment of Patients with Gastrointestinal Stromal Tumors
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 22 Oct 2012
DARA BioSciences Launches Soltamox(R), First and Only Liquid Version of Tamoxifen Citrate
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 Sep 2012
Bayer's Stivarga(R) (regorafenib) Tablets Approved by U.S. FDA for Treatment of Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 4 Sep 2012
Pfizer Receives EU Marketing Authorization for INLYTA(R) (Axitinib)
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 10 Aug 2012
Pfizer Reports Results From Phase 3 Study Of Torisel (temsirolimus) In Combination With Bevacizumab In Advanced Renal Cell Carcinoma (RCC)
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2012
Phase 3 Data on Regorafenib Met Primary Endpoint Showing Significant Improvement in Progression-Free Survival in Patients with GIST
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2012
Phase III Data on Bayer's Regorafenib Met Primary Endpoint Showing Significant Improvement in Progression-Free Survival in Patients with GIST
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 Apr 2012
Jazz Pharmaceuticals Enters Definitive Agreement to Acquire EUSA Pharma
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 16 Apr 2012
Spectrum Pharmaceuticals Commences Tender Offer for All Outstanding Shares of Allos Therapeutics
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 5 Apr 2012
Spectrum Pharmaceuticals to Acquire Allos Therapeutics: Acquisition Expected to Be Accretive on a Cash Basis in Q4 of 2012
Biopharmaceuticals Mergers & Acquisiitons

HSMN NewsFeed - 2 Feb 2012
EUSA Pharma Acquires Development and Commercialization Rights to ASPAREC(R) for Treatment of Acute Lymphoblastic Leukemia from Alizé Pharma
Biopharmaceuticals Oncology Acquisitions

HSMN NewsFeed - 27 Jan 2012
U.S. Food And Drug Administration Approves Pfizer’s INLYTA(R) (axitinib) For Patients With Previously Treated Advanced Renal Cell Carcinoma (RCC)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 20 Jan 2012
Allos Therapeutics Receives Negative Opinion from the CHMP on FOLOTYN
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 18 Nov 2011
EUSA Pharma Announces FDA Approval of Orphan Drug ERWINAZE(TM) for Treatment of Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 17 Aug 2011
Allos Therapeutics Initiates Phase 3 Registration Trial of FOLOTYN(R) in Newly Diagnosed Patients with Peripheral T-Cell Lymphoma Following Treatment with a CHOP-based Regimen
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 20 May 2011
SUTENT(R) Receives U.S. FDA Approval For Advanced Pancreatic Neuroendocrine Tumors
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 23 Mar 2011
Access Pharmaceuticals Appoints Industry Executive Anthony Mottola as Vice President of Managed Care and Market Access
Biopharmaceuticals Drug Delivery Oncology Personnel

HSMN NewsFeed - 31 Jan 2011
Erchonia Laser May Help Cancer Patients With Radiation Treatments
Devices Oncology

HSMN NewsFeed - 2 Dec 2010
SUTENT(R) Receives European Approval for a New Indication in Progressive Pancreatic Neuroendocrine Tumors (NET)
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 27 Sep 2010
Pfizer Discontinues Phase 3 Trial of SUTENT(R) in Advanced Castration-Resistant Prostate Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Jul 2010
Abraxis BioScience and Specialised Therapeutics Announce Approval to Market ABRAXANE for Metastatic Breast Cancer in New Zealand
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 23 Jul 2010
ABRAXANE(R) Approved for Marketing in Japan for Breast Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 15 Jun 2010
Galera Therapeutics Secures Funding for New Cancer Treatment
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 8 Jun 2010
New ABRAXANE(R) Data Demonstrates Potential in Patients with Advanced and Malignant Melanoma, Among the Toughest Cancers to Treat
Biopharmaceuticals Oncology

HSMN NewsFeed - 24 Mar 2010
ondansetron RapidFilm(TM) Approved in 16 European Countries
Biopharmaceuticals Drug Delivery Oncology Regulatory

HSMN NewsFeed - 17 Mar 2010
FDA Accepts Filing of Ondine's Pre-Market Approval (PMA) Application for Periowave(TM) Photodisinfection System
Devices Dental FDA

HSMN NewsFeed - 17 Mar 2010
ABRAXANE Meets Primary Endpoint in Phase 3 Trial for Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Mar 2010
EUSA Pharma Completes Establishment of Commercial Infrastructure With Appointment of President for Europe and International Region
Biopharmaceuticals Personnel

HSMN NewsFeed - 22 Jan 2010
Data Show Progression-Free Survival Advantage with Sutent(R) in Patients with Pancreatic Neuroendocrine Tumors
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 Jan 2010
Ondine Files PMA Submission for Periowave(TM) Photodisinfection System
Devices Dental FDA

HSMN NewsFeed - 15 Dec 2009
Access Pharmaceuticals Appoints Sales and Marketing Executive
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 28 Oct 2009
SciClone Announces Corporate Restructuring and Workforce Reduction
Biopharmaceuticals

HSMN NewsFeed - 23 Oct 2009
Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Patients With Non-Responsive Thyroid Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Oct 2009
FDA Approves Elitek(R) (rasburicase) for Management of Plasma Uric Acid Levels in Adults with Leukemia, Lymphoma, and Solid Tumors Receiving Anti-Cancer Therapy
Biopharmaceuticals FDA

HSMN NewsFeed - 30 Sep 2009
Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 25 Sep 2009
Allos Therapeutics' FOLOTYN First and Only FDA-Approved Therapy for Relapsed or Refractory Peripheral T-cell Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 22 Sep 2009
Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Aug 2009
Results from a Phase 2 Study of ABRAXANE(R) In Combination With Carboplatin Show Clinical Activity in the First Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Jul 2009
Access Pharmaceuticals Announces New MuGard Commercial Strategy in North America
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 Jul 2009
Access Pharmaceuticals Announces Commercial Launch of MuGard(TM) in Norway by SpePharm
Biopharmaceuticals

HSMN NewsFeed - 23 Jul 2009
MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 25 Jun 2009
Sutent Significantly Improved Progression-Free Survival for Patients with Advanced Pancreatic Islet Cell Tumors
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Jun 2009
Pfizer Discontinues SUN 1094 Trial of Sunitinib plus Paclitaxel in Advanced Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Apr 2009
SpePharm Announces the European Launches of Two New Products: MuGard and Xerotin
Biopharmaceuticals Oncology Distribution

HSMN NewsFeed - 2 Apr 2009
Pfizer Discontinues One Sunitinib Phase 3 Trial in Advanced Breast Cancer; Other Advanced Breast Cancer Trials Continue
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 Mar 2009
EUSA Pharma Completes the European Launch of CAPHOSOL(R) for Prevention and Treatment of Oral Mucositis Caused by Cancer Therapy
Biopharmaceuticals

HSMN NewsFeed - 12 Mar 2009
Sutent Significantly Increases Progression Free Survival for Patients with Advanced Pancreatic Islet Cell Tumors, Study Stopped Early
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Feb 2009
Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
Biopharmaceuticals Licensing

HSMN NewsFeed - 4 Feb 2009
Abraxis BioScience Launches ABRAXANE in Germany
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Feb 2009
Pfizer's Sutent is Recommended as First-Line Treatment for Kidney Cancer Patients by British Health Agency
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 20 Oct 2008
High-Dose Zevalin(R) With Tandem Stem Cell Infusion Produces 87 Percent Overall Survival in Relapsed/Refractory or High Risk Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Oct 2008
Abraxis BioScience and Specialised Therapeutics Australia Announce Approval to Market ABRAXANE for Metastatic Breast Cancer in Australia
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 8 Oct 2008
One Year of GATTEX(TM) Therapy Safely Reduces Parenteral Nutrition Dependence for Patients with Short Bowel Syndrome
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 3 Sep 2008
Access Pharmaceuticals Retains Piper Jaffray to Augment Strategic Partnering Efforts
Biopharmaceuticals

HSMN NewsFeed - 24 Jul 2008
Medivisor Inc. Announces New Sales and Marketing Agreement for Mucotrol(TM) With Cura Pharmaceutical Co Inc.
Biopharmaceuticals Drug Delivery

HSMN NewsFeed - 14 Jul 2008
Abraxis BioScience Announces Approval to Market ABRAXANE for Metastatic Breast Cancer in China
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 10 Jul 2008
Access Pharmaceuticals Signs Merger Agreement to Acquire MacroChem Corp.
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 2 Jun 2008
ABRAXANE(R) in Combination with Trastuzumab and Carboplatin Evaluated as First-Line Treatment for Patients with HER2-Positive Metastatic Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Jun 2008
Combination Therapy of Solvent-Free ABRAXANE(R) and the Targeted Therapy Bevacizumab Evaluated as First-Line Treatment for Metastatic Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Jun 2008
MethylGene Reports Clinical Data for MGCD0103 at the 44th American Society of Clinical Oncology (ASCO) Annual Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Jun 2008
Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2008
New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2008
New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 May 2008
Phase 3 GATTEX(TM) Results Presented at Annual Digestive Disease Week Congress Highlight Potential New Treatment in Short Bowel Syndrome
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 9 May 2008
EUSA Pharma Completes Acquisition Of Cytogen Corporation
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 23 Apr 2008
Abraxis BioScience Reports Promising Clinical Data in Advanced Pancreatic Cancer Using a Combination of nab-Paclitaxel (ABRAXANE(R)) and Gemcitabine (Gemzar(R))
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Apr 2008
Abraxis BioScience Announces Approval to Market ABRAXANE for Metastatic Breast Cancer in Korea
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 17 Mar 2008
Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
Biopharmaceuticals

HSMN NewsFeed - 17 Mar 2008
NPS Reports Successful GATTEX(TM) Extension Study
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 17 Mar 2008
Abraxis Bioscience Announces Filing of Marketing Application in Japan for ABRAXANE in the Treatment of Breast Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 13 Mar 2008
Hawthorn Pharmaceuticals, Inc. Receives FDA Approval on Granisol(TM) Oral Solution
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 11 Mar 2008
EUSA Pharma to Acquire US Specialty Oncology Company Cytogen
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 3 Mar 2008
Pfizer to Acquire Serenex to Extend Oncology Pipeline and Access Novel Technology Platform
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 27 Feb 2008
Hospira Launches Generic Irinotecan Injection
Biopharmaceuticals Oncology Generics

HSMN NewsFeed - 7 Feb 2008
Abraxis Bioscience Establishes Global Leadership Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 4 Feb 2008
EKR Therapeutics and PDL BioPharma Sign Asset Purchase Agreement for Cardiovascular Products
Biopharmaceuticals Acquisitions Cardiology

HSMN NewsFeed - 22 Jan 2008
Abraxis Receives Approval from EU Commission to Market ABRAXANE for Metastatic Breast Cancer in Europe
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 17 Jan 2008
Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 Jan 2008
Access Pharmaceuticals Closes Acquisition of Somanta Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 26 Dec 2007
Access Pharmaceuticals Appoints Jeffrey B. Davis as CEO
Biopharmaceuticals Personnel

HSMN NewsFeed - 17 Dec 2007
Otsuka Pharmaceutical Acquires Rights to IV Busulfex From PDL BioPharma
Biopharmaceuticals Oncology Acquisitions

HSMN NewsFeed - 12 Dec 2007
Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke
Biopharmaceuticals Neurology Interventional

HSMN NewsFeed - 26 Nov 2007
Wyeth's TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 12 Nov 2007
Cytogen Announces Executive Management Changes
Biopharmaceuticals Personnel

HSMN NewsFeed - 8 Nov 2007
Access Pharmaceuticals Announces $19.5 Million Recapitalization
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Oct 2007
Abraxis BioScience Receives a Positive Opinion in Europe from the CHMP for the Approval of ABRAXANE for the Treatment of Metastatic Breast Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 18 Oct 2007
Abraxis BioScience and Biocon Limited Announce Approval of ABRAXANE in India for the Treatment of Breast Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 16 Oct 2007
FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 15 Oct 2007
Abraxis Bioscience Reaches Agreement with the FDA Following Special Protocol Assessment for Phase III Trial of ABRAXANE in Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 1 Oct 2007
Carrington and DaySpring Pharma Extend and Formalize Agreement for Distribution of Diabetic and Radiation Products Into Physician Market
Biopharmaceuticals Wound Care Distribution

HSMN NewsFeed - 26 Sep 2007
NPS Pharmaceuticals and Nycomed Announce Licensing Agreement for GATTEX(TM) in Territories Outside North America
Biopharmaceuticals Gastroenterology Licensing

HSMN NewsFeed - 20 Sep 2007
European Committee Issues Positive Opinion on Wyeth's TORISEL(TM) for Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 19 Sep 2007
CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 12 Sep 2007
Innocoll Enters Into Collaboration With TGR Biosciences for Development of a Novel Wound Healing Product
Biopharmaceuticals Drug Delivery Wound Care

HSMN NewsFeed - 11 Sep 2007
ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 Sep 2007
ImClone Settles Patent Lawsuit and Gains Rights to Additional Intellectual Property
Biopharmaceuticals Oncology Litigation Licensing

HSMN NewsFeed - 6 Sep 2007
Pfizer Oncology Initiates Global Phase III Trial to Evaluate Sunitinib Malate Combined with Erlotinib in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Aug 2007
Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
Biopharmaceuticals

HSMN NewsFeed - 16 Aug 2007
Carrington and DaySpring Pharma Sign Term Sheet for Distribution of Diabetic and Radiation Products Into Physician Market
Biopharmaceuticals Distribution

HSMN NewsFeed - 15 Aug 2007
EKR Therapeutics Achieves Key Growth Milestone with the Acquisition of Rights from Pacira Pharmaceuticals to DepoDur(R), a Novel Extended-Release Opioid Analgesic for Post Operative Pain
Biopharmaceuticals Distribution

HSMN NewsFeed - 15 Aug 2007
EKR Therapeutics Raises Over $13 Million in a Series C Financing Round From New and Existing Investors
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 8 Aug 2007
Abraxis BioScience Announces Licensing Agreement with Biocon Limited for the Commercialization of ABRAXANE in India
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 27 Jul 2007
Bristol-Myers Squibb and Imclone Systems Significantly Expand ERBITUX Clinical Development Program
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 Jul 2007
Myriad Genetics Launches New Molecular Diagnostic Test
Diagnostics Oncology

HSMN NewsFeed - 12 Jul 2007
Data Available From ERBITUX(R) Phase III Study in First-Line Treatment of Advanced Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 Jul 2007
Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 Jun 2007
Serenex Secures $31 Million in Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 26 Jun 2007
Nuvelo Resumes Development of Alfimeprase in Multiple Blood-Clot Related Indications
Biopharmaceuticals

HSMN NewsFeed - 15 Jun 2007
Former President and CEO of Biomira Alex McPherson Joins Carrington Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 11 Jun 2007
Cytogen Announces New Sales and Marketing Leadership with the Appointment of Stephen A. Ross
Biopharmaceuticals Personnel

HSMN NewsFeed - 11 Jun 2007
FDA Accepts and Grants Priority Review of ERBITUX(R) (Cetuximab) sBLA for Overall Survival in Patients with Advanced Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 5 Jun 2007
Extensive Clinical Data on ERBITUX(R) Presented at the 2007 ASCO Annual Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2007
New Data Shows Promising Antitumor Activity with nab-paclitaxel (ABRAXANE(R)) in Combination and as a Single Agent for the Treatment of Lung and Ovarian Cancers
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2007
GSK's Pazopanib Shows Positive Results in Patients With Advanced Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2007
New Data Show Pfizer's Axitinib Prolonged Overall Survival in Advanced Pancreatic Cancer When Combined with Standard of Care Chemotherapy
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2007
Cytokinetics Announces the Presentation of Clinical Trials Data at the 2007 Annual Meeting of the American Society of Clinical Oncology
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jun 2007
Single-Agent SUTENT Prolonged Progression-Free Survival across All Advanced Kidney Cancer Patient Risk Groups, Including Those with Poorest Prognoses, Data Show
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jun 2007
Glaxosmithkline Reports Positive New Data on Tykerb(R)(Lapatinib) at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jun 2007
Phase III Ixabepilone Study Demonstrated Significant Improvement in Progression-Free Survival in Patients With Advanced Metastatic Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Jun 2007
New Data Evaluating SUTENT, CP-751,871 and Axitinib in Patients with Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Jun 2007
ABRAXANE Demonstrates Longer Progression-Free Survival versus Taxotere in the Treatment of First-Line Metastatic Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Jun 2007
Data Presented at ASCO Showed TORISEL Significantly Increased Quality-Adjusted Survival for Patients With Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 May 2007
FDA Approves TORISEL, a Targeted First-in-Class mTOR Inhibitor for the Treatment of Advanced Kidney Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 30 May 2007
Data Published in the New England Journal of Medicine Showed TORISEL Extended Median Overall Survival for Patients with Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 May 2007
Amgen Names David Lacey, M.D., Senior Vice President, Head of Research
Biopharmaceuticals Personnel

HSMN NewsFeed - 22 May 2007
Outcomes Data Continue to Demonstrate Value of Cytogen's PROSTASCINT(R) to Predict Prognosis in Prostate Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 21 May 2007
Carrington President and Chief Executive Officer Carlton E. Turner Announces Plan to Retire on December 31, 2008
Biopharmaceuticals Personnel

HSMN NewsFeed - 15 May 2007
Senior Development Executive Joins Serenex
Biopharmaceuticals Personnel

HSMN NewsFeed - 10 May 2007
ProCertus BioPharm, Inc. Closes $2.3 Million Series A Financing Led by Venture Investors LLC
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 27 Apr 2007
Access Pharmaceuticals Announces Expansion of ProLindac(TM) Clinical Trial Sites
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Apr 2007
Access Pharmaceuticals Signs Definitive Merger Agreement With Somanta Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 18 Apr 2007
Carrington and Primus Pharmaceuticals Sign Long-Term Supply and Patent Licensing Agreements for Acemannan Hydrogel(TM)
Biopharmaceuticals Licensing

HSMN NewsFeed - 16 Apr 2007
Randomized Phase III Trial Showed ERBITUX Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 Apr 2007
Data Available from ERBITUX(R) Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Apr 2007
Survival Data Available From ERBITUX(R) Study in First-Line Treatment of Advanced Head and Neck Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 Mar 2007
Nuvelo Receives FDA Fast Track Status for rNAPc2 in Both First- and Second-Line Treatment of Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 21 Feb 2007
Access Pharmaceuticals Signs Letter of Intent to Acquire Somanta Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 8 Feb 2007
Pfizer's Sutent Receives FDA Approval to Include New First-Line Advanced Kidney Cancer Data in Label
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 8 Feb 2007
Access Pharmaceuticals Appoints Esteban Cvitkovic, M.D. as Director and Vice Chairman (Europe)
Biopharmaceuticals Personnel

HSMN NewsFeed - 8 Feb 2007
Seven-Year Survival Data Demonstrate use of Cytogen's PROSTASCINT(R) Independently Predicts Recurrence of Prostate Cancer
Biopharmaceuticals Radiology Oncology

HSMN NewsFeed - 5 Feb 2007
ImClone Systems Incorporated and Bristol-Myers Squibb Announce Application In Japan for Use of ERBITUX in Metastatic Colorectal Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 25 Jan 2007
European Association of Nuclear Medicine Journal Article Reports New Data Regarding Administration of QUADRAMET(R) with Chemotherapy in Hormone Refractory Prostate Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Jan 2007
Vicus Therapeutics Announces the FDA has Allowed the Phase 2 Trial of VT-122 for the Treatment of Cachexia in Patients With Advanced Lung Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 10 Jan 2007
ERBITUX(R) Phase III Study Meets Primary Endpoint In First-Line Treatment of Metastatic Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Jan 2007
Access Pharmaceuticals Names Stephen R. Seiler as President and CEO
Biopharmaceuticals Personnel

HSMN NewsFeed - 4 Jan 2007
Expanded Role for Cytogen's PROSTASCINT(R) Incorporated Into NCCN(R) Clinical Practice Guidelines
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Dec 2006
Trillium's TTI-1612 product receives orphan drug designation in Europe and the United States
Biopharmaceuticals Gastroenterology Regulatory

HSMN NewsFeed - 18 Dec 2006
American Cancer Society Journal Article Reports New Data Regarding Repeated Administration of QUADRAMET(R)
Biopharmaceuticals Oncology

HSMN NewsFeed - 13 Dec 2006
Access Pharmaceuticals Receives MuGard(TM) Marketing Clearance From the FDA
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 11 Dec 2006
Nuvelo and Bayer Healthcare Announce Phase 3 Trials of Alfimeprase in Patients With Acute Peripheral Arterial Occlusion and Catheter Occlusion Did Not Meet Primary Endpoints
Biopharmaceuticals

HSMN NewsFeed - 5 Dec 2006
Carrington Files Lawsuit Against Individual for Libelous and Disparaging Statement and Unauthorized Use of Trademark
Biopharmaceuticals Litigation

HSMN NewsFeed - 15 Nov 2006
Pharmion Acquires Cabrellis Pharmaceuticals, Gains Rights to Amrubicin for North America and the European Union
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 6 Nov 2006
Nuvelo Announces Presentations on Alfimeprase and rNAPc2 at The American Heart Association Scientific Sessions 2006
Biopharmaceuticals Cardiology

HSMN NewsFeed - 6 Nov 2006
Survival Data Available from Two Randomized ERBITUX Studies in Metastatic Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Nov 2006
Carrington's DelSite Subsidiary Presents Data on Needle-Free Vaccine Technology
Biopharmaceuticals Drug Delivery

HSMN NewsFeed - 26 Oct 2006
Cytogen Appoints Kevin Bratton New Chief Financial Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 23 Oct 2006
DelSite Presents Influenza Nasal Powder Vaccine Data
Biopharmaceuticals Drug Delivery

HSMN NewsFeed - 13 Oct 2006
BioAlliance Pharma Receives Marketing Authorisation for Its First Product, Loramyc(R)
Biopharmaceuticals Regulatory

HSMN NewsFeed - 12 Oct 2006
MGI PHARMA Receives Approvable Letter for Saforis(TM) (Glutamine) Powder in UpTec(TM) for Oral Suspension
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 12 Oct 2006
Endo Pharmaceuticals Acquires RxKinetix, Inc.
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 12 Oct 2006
EKR Therapeutics Acquires Exclusive License for Gelclair(R) from Helsinn Healthcare SA
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 11 Oct 2006
Cytogen Acquires North American Marketing Rights to CAPHOSOL(R) for Treatment of Both Oral Mucositis and Dry Mouth
Biopharmaceuticals Licensing

HSMN NewsFeed - 28 Sep 2006
Carrington Subsidiary to Develop Needle-less Delivery of Cervical Cancer Vaccine With the National Cancer Institute (NCI)
Biopharmaceuticals Drug Delivery Oncology

HSMN NewsFeed - 19 Jul 2006
Nuvelo Appoints H. Ward Wolff as Chief Financial Officer and Jill M. Pergande as Vice President, Human Resources
Biopharmaceuticals Personnel

HSMN NewsFeed - 6 Jul 2006
Nuvelo Announces Publication of Phase 2 Alfimeprase Study Results in Central Venous Catheter Occlusion
Biopharmaceuticals

HSMN NewsFeed - 29 Jun 2006
Nuvelo Expands Depth in Manufacturing and Development With Key Additions to Management Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 1 Jun 2006
Nuvelo Announces Completion of Phase 2 Heparin Replacement Trial Evaluating rNAPc2 in Acute Coronary Syndromes
Biopharmaceuticals Cardiology

HSMN NewsFeed - 17 May 2006
Carrington Appoints New Vice President, Corporate Sales & Marketing
Biopharmaceuticals Personnel

HSMN NewsFeed - 17 May 2006
DelSite President Resignation Announced
Biopharmaceuticals Drug Delivery Personnel

Return to NewsFeed

Additional items found! 141

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 141 additional stories matching:
mucositis
(Password required)

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!